

AMENDMENT UNDER 37 C.F.R. § 1.116
Application No.: 10/534,290

Attorney Docket No.: Q87757

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended):** A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)- 2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl) amino]ethyl]acetic acid anilide or a salt thereof as an active ingredient, wherein the subject is not suffering from diabetes.
2. **(previously presented):** The method according to claim 1, wherein the overactive bladder is a result of benign prostatic hyperplasia.
3. **(previously presented):** The method according to claim 1, wherein the subject has urinary urgency.
4. **(previously presented):** The method according to claim 1, wherein the subject has urinary urge incontinence.
5. **(previously presented):** The method according to claim 1, wherein the subject has pollakiuria.
6. **(currently amended):** A method for treating overactive bladder comprising administering to a subject in need thereof, a pharmaceutically effective amount of (R)-2-(2-

aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, in its free base form, as an active ingredient, wherein the subject is not suffering from diabetes.

7. **(previously presented):** The method according to claim 6, wherein the overactive bladder is a result of benign prostatic hyperplasia.

8. **(previously presented):** The method according to claim 6, wherein the subject has urinary urgency.

9. **(previously presented):** The method according to claim 6, wherein the subject has urinary urge incontinence.

10. **(previously presented):** The method according to claim 6, wherein the subject has pollakiuria.

11. **(previously presented):** The method according to claim 1, wherein the subject is human.

12. **(previously presented):** The method according to claim 6, wherein the subject is human.